Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)Sumanta K. Pal(City of Hope), Jeremy O. Jones(City of Hope)CancerDecember 19, 201710.1002/cncr.31161Cited by 88SaveCiteExport RISWatch citationsRelated PapersNivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial|Nature Medicine|2022|453CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma|Cancer Discovery|2024|133